Inactive Instrument

Pressure BioSciences, Inc. Stock Nasdaq

Equities

US74112E1091

Medical Equipment, Supplies & Distribution

End-of-day quote Nasdaq
- USD - Intraday chart for Pressure BioSciences, Inc.
Sales 2022 1.73M Sales 2023 1.98M Capitalization 7.77M
Net income 2022 -16M Net income 2023 -29M EV / Sales 2022 21.1 x
Net Debt 2022 20.53M Net Debt 2023 22.8M EV / Sales 2023 15.5 x
P/E ratio 2022
-0.81 x
P/E ratio 2023
-0.22 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.34%
More Fundamentals * Assessed data
Pressure BioSciences, Inc. Partners with Vita-Forte to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray CI
Transcript : Pressure BioSciences, Inc. - Special Call
Pressure BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC. CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC. CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009 MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd CI
More news

Latest transcript on Pressure BioSciences, Inc.

Managers TitleAgeSince
Chief Executive Officer 73 78-07-31
Chief Tech/Sci/R&D Officer 70 06-04-23
Chief Tech/Sci/R&D Officer 59 06-04-02
Members of the board TitleAgeSince
Chief Executive Officer 73 78-07-31
Director/Board Member 71 13-02-07
Chairman 68 11-06-20
More insiders
Pressure BioSciences, Inc. is engaged in the development and sale of enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Its products/services are based on three high-pressure platforms: Ultra Shear Technology (UST), BaroFold Technology (BaroFold), and Pressure Cycling Technology (PCT). The UST platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. PCT utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The BaroFold platform provides valuable contract services and GMP manufacturing equipment to the biopharmaceutical industry.
More about the company